Article Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study
|
|
- Michael Holmes
- 6 years ago
- Views:
Transcription
1 RBMOnline - Vol 13. No Reproductive BioMedicine Online; on web 19 May 2006 Article Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study Willem Verpoest studied medicine, and graduated as an obstetrician gynaecologist at the Catholic University of Louvain, Belgium, in He developed an interest in reproductive medicine working under Michael Hull and David Cahill in Bristol, UK, and Paul Devroey and Andre Van Steirteghem in Brussels, Belgium, and is currently Fellow at the Centre for Reproductive Medicine at the Free University of Brussels. He is clinical tutor and clinical coordinator for patients undergoing preimplantation genetic diagnosis, one of the main practices at this centre. His main interests are reproductive endocrinology and genetics, and reproductive surgery. Dr Willem Verpoest Willem MJA Verpoest 1,3, Efstratios Kolibianakis 2, Evangelos Papanikolaou 1, Johan Smitz 1, Andre Van Steirteghem 1, Paul Devroey 1 1 Academic Hospital of the Vrije Universiteit Brussel, 101 Laarbeeklaan, B-1090 Brussels, Belgium; 2 Unit for Human Reproduction, 1st Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Greece 3 Correspondence: willem.verpoest@az.vub.ac.be; Tel: ; Fax: Abstract This prospective randomized pilot study was aimed at investigating the effect of the novel addition of aromatase inhibitors to an ovarian stimulation protocol for IVF or intracytoplasmic sperm injection, on endocrine parameters including serum androgen, oestrogen, progesterone, LH and FSH concentrations. The patients were randomized to receiving letrozole (group A; n = 10), versus no letrozole (group B; n = 10) in an ovarian stimulation protocol with recombinant FSH 150 IU/day starting on day 2 of the cycle, and gonadotrophin-releasing hormone antagonist 0.25 mg/day starting on day 6 of the cycle. Median LH concentrations were significantly higher (P P < 0.01) in group A versus group B during letrozole administration. Median serum oestradiol concentrations were lower in group A versus group B, and median serum FSH, testosterone and androstenedione concentrations were higher in group A versus group B, throughout the follicular phase, without reaching significance. Median endometrial thickness was significantly higher (P P < 0.05) in group A versus group B on the day of human chorionic gonadotrophin administration. Pregnancies were achieved. This pilot study supports the idea that aromatase inhibitors can contribute to normal potential of implantation and follicular response, without having negative anti-oestrogenic effects. Keywords: androgens, anti-oestrogens, aromatase inhibitors, ICSI, letrozole, ovarian stimulation 166 Introduction The use of aromatase inhibitors has been shown to be effective in ovulation induction, and appears to be associated with fewer side effects than clomiphene citrate (CC) (Holzer et al., 2006). Moreover, it is associated with improved endometrial thickness, greater follicular response to gonadotrophins and a lower risk of ovarian hyperstimulation syndrome and multiple pregnancies (Metwally and Casper, 2004; Metwally et al., 2005). Aromatase inhibitors such as letrozole are thought to induce the development of a follicle by releasing the pituitary gland from oestrogenic negative feedback, primarily by inhibition of the conversion of androstenedione to oestrone in the ovary. However, there does not appear to be depletion of the central oestrogen receptors, as opposed to what happens when clomiphene citrate is used, thus allowing normal central feedback mechanisms, and therefore monofollicular rather than multifollicular development in most cases (Casper, 2003). Lack of oestrogen receptor depletion in peripheral tissues such as endometrium is the basis for better endometrial development when using aromatase inhibitors (Metwally and Casper, 2001, 2003). Aromatase inhibition is also thought to improve follicular response by augmenting follicular FSH receptor expression as a result of raised intra-ovarian androgen concentrations, although solid evidence for this mechanism is lacking (Metwally and Casper, 2001, 2003). Aromatase inhibition is also thought to improve follicular response by augmenting FSH receptor expression as a result of raised intra-ovarian concentrations, although solid evidence for this mechanism is lacking (Metwally and Casper 2001, 2003; Hugues and Cédrin-Durnerin, 2005). There is little information on the use of aromatase inhibitors in association with
2 gonadotrophins in ovarian stimulation for IVF/intracytoplasmic sperm injection (ICSI) (Holzer et al., 2006), or on the effect of aromatase inhibitors on serum endocrine parameters, especially on serum androgen concentrations (Metwally et al., 2005). Previous studies have investigated the co-administration, either concomitantly or sequentially, of aromatase inhibitors and gonadotrophins for ovulation induction, and only more recently some limited data emerged on the co-administration of aromatase inhibitors in ovarian stimulation (Metwally et al., 2005). The aim of this pilot study was to investigate the effect of the co-administration of aromatase inhibitors on endocrine parameters, including serum testosterone, androstenedione, oestrogen, progesterone, LH and FSH concentrations, in an ovarian stimulation protocol using recombinant gonadotrophins and gonadotrophin releasing hormone (GnRH) antagonists for IVF/ICSI. Materials and methods This was a prospective, randomized pilot study, at a University Centre for Reproductive Medicine, over an 8-month period from January until September Inclusion criteria were: (i) subfertility for more than 1 year requiring IVF/ICSI, (ii) age younger than 39 years, (iii) first or second IVF/ICSI trial and (iv) use of ejaculated spermatozoa only. Exclusion criteria were: (i) patients belonging to any of the WHO classification groups (I, II or III) of ovulatory disorders, (ii) oligomenorrhoea (menstrual cycle >35 days), (iii) polymenorrhoea (menstrual cycle<21 days), (iv) early follicular phase FSH concentrations 15 IU/l, (v) endometriosis American Fertility Society (AFS) grades III and IV, (vi) IVF/ICSI with preimplantation genetic diagnosis (PGD) and (vii) body mass index (BMI) 28. Prestudy investigations included: full blood count, renal and liver function tests, thyroid function tests (thyroid-stimulating hormone, thyroxin, antithyroid peroxidase antibodies), prolactin, early follicular phase FSH, LH, oestradiol, progesterone concentrations, and both male and female karyotyping. Transvaginal ultrasound was performed in all patients prior to recruitment. Informed consent was obtained from all patients. The trial was approved by the institutional ethical committee. Patient population Twenty patients with regular ovulation and aged <39 years of age were recruited and randomized according to a computer generated randomization list, 10 in each treatment group. Indications for treatment were similar across the two groups. Ovarian stimulation In group A (n = 10), patients received letrozole (Femara; Novartis Pharma, Basel, Switzerland) 2.5 mg daily from day 2 until day 6 of the cycle and recombinant FSH (rhfsh) (Puregon; NV Organon, Oss, The Netherlands) starting on day 2 of the cycle. In group B (n = 10), ovarian stimulation was performed with rhfsh only, starting on day 2 of the cycle. In both groups, a constant daily dose of 150 IU rhfsh was used for stimulation and GnRH antagonist (ganirelix, Orgalutran; NV Organon) 0.25 mg/day was always started on day 6 of the cycle until the day of ovulation triggering with human chorionic gonadotrophin (HCG). Final oocyte maturation was achieved by the administration of HCG (Pregnyl; Organon) as soon as 3 follicles of 17 mm were present at ultrasound. Steroid concentrations were measured, but were not taken into consideration for the decision on ovulation triggering by HCG administration, which was based exclusively on follicular development. Ultrasound was performed on day 6 of stimulation and thereafter as necessary in order to ensure that HCG was injected on the first day on which the patient had 3 follicles of 17 mm. For that purpose, a follicular growth of 2 mm per day was assumed to be present (Kolibianakis et al., 2004). Analysis of serum testosterone, androstenedione, sex hormone binding globulin (SHBG), oestradiol, progesterone, FSH and LH concentrations was performed on days 2, 4, 6, 7, 8 and 10 of the cycle (i.e. days 1, 3, 5, 6, 7 and 9 of the ovarian stimulation). IVF/ICSI procedures The details of the IVF and ICSI procedure have been described previously (Devroey et al., 1995; Joris et al., 1998; Van Steirteghem et al., 1998). The embryo transfer was performed either on day 3 or day 5 after oocyte retrieval. Luteal support consisted of a single dose of HCG 7 days after HCG administration for ovulation triggering. Hormonal and ultrasound assessment Serum LH, FSH, HCG, oestradiol and progesterone were measured with the automated Elecsys immunoanalyser (Roche Diagnostics, Mannheim, Germany). Intra-assay and interassay coefficients of variation (CV) were <3 and <4% for LH, <3 and <6% for FSH, <5 and <7% for HCG, <5 and <10% for oestradiol and <3 and <5% for progesterone respectively. Ultrasound was performed on day 6 of the cycle, plus on the day of HCG, and on other days throughout the stimulation when considered appropriate. Endometrial thickness was measured at the thickest longitudinal plane. Statistical analysis Statistical analysis was carried out using Statistics Package for Social Sciences data editor version Continuous variables were analysed with the Mann Whitney U-test. - A P-value of <0.05 was considered significant. Variables are expressed as median (range). Results Patient characteristics were similar in the two groups (Table 1). The median number of previous treatment cycles was 0.2 (SD 0.42) in the letrozole + FSH group versus 0.1 (SD 0.33) in the FSH only group. Indications for infertility treatment were similar in both groups (eight oligoasthenoteratozoosperm ia (OAT), one idiopathic and one tubal in the letrozole + FSH group, versus seven OAT, two idiopathic and one tubal in the FSH only group). A non-significant difference in the median age was present between the two groups compared [29.9 (SD 2.78) years in the letrozole + FSH group, versus 32.7 (SD 5.82) 167
3 Table 1. Patient characteristics and treatment outcome. Group FSH + FSH + letrozole no letrozole No. of patients Median age in years (SD) 29.9 (2.78) 32.7 (5.82) Indications Andrological 8 7 Tubal 1 1 Unexplained 1 2 Mean no. of oocytes (SD) 13.8 (9.24) 9.6 (7.73) Fertilization rate % (SD) 63.3 (19.61) (18.36) Mean no. of embryos transferred (SD) 1.60 (0.52) 1.60 (0.84) Mean no. of embryos cryopreserved (SD) 2.9 (3.81) 2.55 (4.21) Positive HCG rate per cycle % Clinical pregnancy rate per cycle % Implantation rate % (ratio) (5/10) 12.5 (2/10) The results in the two groups are not statistically different using the Wilcoxon signed rank test. HCG = human chorionic gonadotrophin. in the FSH only group]. The median total dose of recombinant gonadotrophins used per treatment cycle did not differ between the two groups [1575 IU (SD 285.0) in the letrozole + FSH group versus 1650 IU (SD 290.6) in the FSH only group]. Median LH concentrations were significantly higher (P < 0.01) in the letrozole + FSH group versus the FSH only group, on day 4 of the cycle [6.3 IU/l (range IU/l) versus 3.3 IU/l (range IU/l)], and on day 6 of the cycle [2.9 IU/l (range IU/l) versus 1.4 IU/l (range IU/l)] respectively (P < 0.01) (Figure 1). Oestradiol concentrations were lower in the letrozole + FSH group versus the FSH only group (Figure 2), while testosterone (Figure 3), androstenedione (Figure 4) and FSH (Figure 5) concentrations were higher in the letrozole + FSH group versus the FSH only group, throughout the follicular phase, although these differences did not reach significance. Median endometrial thickness was significantly higher in the letrozole + FSH group versus the FSH only group on the day of HCG administration [10.3 mm (minimum 8.2 mm to maximum 15.2 mm) versus 8.1 mm (minimum 6.0 mm to maximum 12.5 mm) respectively; P < 0.05]. A median of 13.8 (SD 9.24) oocytes was retrieved in the letrozole + FSH group, versus 9.6 (SD 7.73) in the FSH only group (not significant, NS, Table 1). The mean fertilization rate in the letrozole + FSH group was 63.3 versus 77.8% in the FSH only group (NS). In both groups, the mean number of embryos transferred was 1.6; the mean number of embryos frozen in the letrozole + FSH group was 2.9, versus 2.55 in the FSH only group (NS). Five ongoing pregnancies were achieved in the letrozole + FSH group, versus two in the FSH only group. 168 Figure 1. Box plots of serum LH concentrations (IU/l). The pale boxes represent median LH concentrations in the letrozole + FSH group (ovarian stimulation with letrozole associated with recombinant FSH); the darker boxes represent median LH concentrations in the FSH only group (ovarian stimulation with recombinant FSH only). Differences between groups were significant at day 4 (P < 0.01), day 6 (P < 0.01) and day 7 of the cycle (P < 0.01).
4 Figure 2. Box plots of serum oestradiol concentrations (pg/ml). The pale boxes represent median oestradiol concentrations in the letrozole + FSH group (ovarian stimulation with letrozole associated with recombinant FSH); the darker boxes represent oestradiol concentrations in the FSH-only group (ovarian stimulation with recombinant FSH only). Differences were not significant. Figure 3. Box plots of serum testosterone concentrations (μg/l). The pale boxes represent median testosterone concentrations in the letrozole + FSH group (ovarian stimulation with letrozole associated with recombinant FSH); the darker boxes represent median testosterone concentrations in the FSH-only group (ovarian stimulation with recombinant FSH only). Differences were not significant. Figure 4. Box plots of serum androstenedione concentrations (ng/l). The pale boxes represent median androstenedione concentrations in the letrozole + FSH group (ovarian stimulation with letrozole associated with recombinant FSH); the darker boxes represent median androstenedione concentrations in the FSH-only group (ovarian stimulation with recombinant FSH only). Differences were not significant. 169
5 Figure 5. Box plots of serum FSH concentrations (IU/l). The pale boxes represent serum follicle stimulating hormone (FSH) concentrations in the letrozole + FSH group (ovarian stimulation with letrozole associated with recombinant FSH); the darker boxes represent serum FSH concentrations in the FSH-only group (ovarian stimulation with recombinant FSH only). Differences were not significant. 170 Discussion This study was designed to document the extent to which endocrine parameters change when co-administering aromatase inhibitors in ovarian stimulation for IVF/ICSI, using recombinant gonadotrophins and GnRH antagonists. The results of the pilot study show significantly higher (P < 0.01) LH concentrations, lower oestradiol concentrations, and increased FSH and androgen concentrations, although not significantly so, in the group where the aromatase inhibitor letrozole was added to the ovarian stimulation protocol. An acceptable pregnancy rate was achieved in both groups. Serum oestradiol concentrations (Figure 2) are reduced as a result of the anti-oestrogenic effect of the aromatase inhibitor letrozole, and reflect a decrease of proportionate oestradiol concentrations per follicle. This may limit the negative effect of cumulative oestradiol concentrations on oocyte quality and on endometrial receptivity through modulation of steroid receptors, as proposed by previous authors (Simon et al., 1995; Metwally et al., 2005; Papanikolaou et al., 2005). Moreover, supraphysiological oestrogen concentrations during ovarian stimulation are considered to have a detrimental effect on the developing oocyte, the spermatozoa, the developing embryo and blastocyst hatching, as well as on other targets including leptin, the coagulation system and the early developing placenta (Metwally et al., 2005). These effects are thought to result in reduced implantation rates, reduced pregnancy rates and adverse obstetric outcome following reproductive treatment with ovarian stimulation. Therefore, reducing oestrogen concentrations using aromatase inhibitors, as was the case in the present study, may improve reproductive and obstetric outcome. Nevertheless, the oestradiol concentrations attained during ovarian stimulation with concomitant aromatase inhibitor use are sufficiently high, reflecting adequate follicular development and oestrogen biosynthesis in the presence of anti-oestrogens, as previously demonstrated in primate studies (Weil et al., 1999). Clomiphene citrate has been used in association with ovarian stimulation for IVF/ICSI, but significantly higher concentrations of LH concentrations in the follicular and luteal phase were detected, despite antagonist administration, as well as an increased risk of premature LH surge (Tavaniotou et al., 2002). In the present study, significantly increased LH concentrations (P < 0.01, Figure 1) were also observed, an effect that is only to be expected, due to withdrawal of negative feedback on the pituitary and the hypothalamus. However, the effect of letrozole is short-lived, and should not lead to premature ovulation (Metwally et al., 2005). Indeed, a premature LH surge was not observed in any of the patients. Some authors argue that lower oestradiol concentrations during ovarian stimulation as a result of the use of aromatase inhibition, may even be effective in preventing the occurrence of a premature ovarian LH surge (Metwally et al., 2005). A higher number of oocytes were retrieved in the group receiving letrozole. It is postulated that the observed subtle increase in serum testosterone and androstenedione concentrations in the letrozole group (Figures 3 and 4) may reflect even higher intra-ovarian androgen concentrations, thus contributing to improved folliculogenesis by increasing FSH receptor sensitivity. However, it is still unclear to what extent intrafollicular androgen concentrations change during ovarian stimulation and concomitant aromatase inhibition, and larger studies investigating the effect of aromatase inhibition on androgen metabolism are required (Metwally and Casper, 2001, 2003). This study confirms the findings of other studies, i.e. that the use of aromatase inhibitors is effective in achieving adequate follicular response as well as pregnancies in ovulation induction in both ovulating and anovulating patients (Bulun, 2003; Casper, 2003; Fatemi et al., 2003; Healey et al., 2003). The main action of aromatase inhibitors is through the inhibition of negative oestrogen feedback on the pituitary and
6 the hypothalamus during administration, thereby allowing production of higher endogenous concentrations of FSH and follicular recruitment and stimulation. The adjunct use of aromatase inhibitors during ovarian stimulation has been shown to improve follicular response and reduce the amount of gonadotrophins required (Kilic-Okman et al., 2003; Metwally and Casper, 2003). The results of the present study, in which a fixed daily dosage of gonadotrophins was used, did not show a difference in the cumulative dosage of gonadotrophin required. The mean number of oocytes retrieved was higher in the letrozole group, which would appear to indicate that the use of aromatase inhibitors might contribute to successful ovarian stimulation with a lower dosage of gonadotrophins. A lower dosage of gonadotrophins used will reduce cost, improve patient compliance and reduce psychological impact (Heijnen et al., 2004; de Klerk et al., 2006), may reduce adverse early obstetric outcome (Metwally et al., 2005) and in the current climate of moving towards a legal restriction of the number of embryos transferred and single embryo transfer (De Neubourg and Gerris, 2003; De Neubourg et al., 2005), a lower and more physiological stimulation is preferred. Lower stimulation may avoid inadequate endometrial synchrony (endometrial advancement) hence improve endometrial receptivity. The proportion of chromosomal abnormalities in embryos may also be reduced as a result of lower stimulation (Baart et al., 2005). The daily 2.5 mg dose of aromatase inhibitor used in this study was adopted from standard adjuvant breast cancer treatment protocols. Other studies have reported both higher dosages (Al-Fozan et al., 2004; Al-Fadhli et al., 2006), and single dose administration (Metwally et al., 2005). A study reporting the results of a randomized trial of 238 cycles of ovulation induction with 7.5 mg of letrozole versus 100 mg of clomiphene citrate daily for 5 days in women with idiopathic infertility did not show a difference in pregnancy rate; however, the miscarriage rate in the clomiphene citrate group was higher (Al-Fozan et al., 2004). A more recent study comparing a daily dose of letrozole of 2.5 mg versus 5 mg showed a higher pregnancy rate and higher follicle count in the latter group (Al-Fadhli et al., 2006). Metwally and colleagues reported the results of a nonrandomized retrospective analysis of single-dose administration of letrozole 20 mg on day 3 of the cycle, showing adequate effectiveness in inducing ovulation in comparison with a regimen of 2.5 mg daily for 5 days (Metwally and Casper, 2005). Further randomized studies are required to define the optimal dose of aromatase inhibitor in ovulation induction and ovarian stimulation. Contrary to the present study where an aromatase inhibitor was used concomitantly with an ovarian stimulation protocol using recombinant gonadotrophins and GnRH antagonists for IVF/ ICSI, other studies have used aromatase inhibitors in sequential rather than concomitant administration. Potential advantages of sequential rather than concomitant administration include a longer time lag until ovulation, allowing clearance from the system, more time for follicular development, and a lower total dose requirement of gonadotrophins (Healey et al., 2003). Other studies into the use of aromatase inhibitors in ovarian stimulation for IVF/ICSI are rare, and have shown potential use in improving ovarian response without provoking any side effects (Metwally et al., 2005). All studies into the use of aromatase inhibitors published so far are of limited size. Recognizing the limitations of the current study with regard to sample size, sources of potential bias were avoided as the study design was randomized controlled, with a fixed dose of recombinant FSH for ovarian stimulation, and a fixed protocol for ovulation triggering as soon as three or more follicles of 17 mm were seen at ultrasound. The current study, as previously stated was a pilot study. It was not possible to perform a meaningful power analysis in the absence of literature data on the co-administration of letrozole and FSH. The present study, as a first, can serve as a source of such information in the design of further randomized controlled trials on the co-administration of aromatase inhibitors and recombinant gonadotrophins. The lack of power to detect a significant difference in certain comparisons performed should not necessarily be interpreted as lack of a true difference between the two groups. In conclusion, the results of this study into the novel coadministration of the aromatase inhibitor letrozole to an ovarian stimulation protocol using recombinant gonadotrophins and GnRH antagonists for IVF/ICSI demonstrate a significant increase (P < 0.01) in LH concentrations, increased serum androgen concentrations and reduced serum oestradiol concentrations in the group receiving the aromatase inhibitor, resulting in an increase in oocytes retrieved and endometrial thickness. Pregnancies were achieved, supporting the idea that aromatase inhibitors can contribute to normal potential of implantation and follicular response, without having negative anti-oestrogenic effects. Larger randomized studies are needed to document the effect of aromatase inhibitors and their endocrine effects on ovarian stimulation for IVF/ICSI and reproductive outcome. Acknowledgement The authors would like to thank Mr Julian Mitchell for his kind linguistic and syntactic assistance. References Al-Fadhli R, Sylvestre C, Buchett W et al A randomized trial of superovulation with two different doses of letrozole. Fertility and Sterility 85, Al-Fozan H, Al-Khadavi M, Tan SL et al A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertility and Sterility 82, Baart EB, Van Opstal D, Eijkemans MJ et al Does the magnitude of ovarian stimulation or IVF affect chromosomal competence of embryos as assessed by PGS? Abstracts of the 21st Annual Meeting of ESHRE, June Human Reproduction 20 (Suppl. 1) i91 i92 [abstr.]. Bulun SE 2003 Ovulation induction in women with infertility: a new indication for aromatase inhibitors. Fertility and Sterility 80, Casper RF 2003 Letrozole: ovulation or superovulation. Fertility and Sterility 80, de Klerk C, Heijnen EMEW, Macklon NS et al The psychological impact of mild ovarian stimulation combined with single embryo transfer compared with conventional IVF. Human Reproduction 21, De Neubourg D, Gerris J 2003 Single embryo transfer state of the art. Reproductive BioMedicine Online 7, De Neubourg D, Gerris J, Van Royen E et al Impact of a restriction in the number of embryos transferred on the multiple pregnancy rate. European Journal of Obstetrics Gynaecology and Reproductive Biology 124,
7 Devroey P, Tjandraprawira K, Mannaerts B et al.1995 A randomised, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization. Human Reproduction 10, Fatemi HM, Kolibianakis E, Tournaye H et al Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reproductive BioMedicine Online 5, Healey S, Tan SL, Tulandi T et al Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertility and Sterility 80, Heijnen EMEW, Macklon NS, Fauser BCJM 2004 What is the most relevant standard of success in assisted reproduction? The next step to improving outcomes of IVF: consider the whole treatment. Human Reproduction 19, Holzer H, Casper R, Tulandi T 2006 A new era in ovulation induction. Fertility and Sterility 85, Hugues J-N, Cédrin-Durnerin I 2005 Endocrinology in ovarian stimulation. Impact of androgens on fertility physiological, clinical and therapeutic aspects. Reproductive BioMedicine Online 11, Joris H, Nagy Z, Van De Velde H et al Intracytoplasmic sperm injection: laboratory set-up and injection procedure. Human Reproduction 13 (Suppl. 1), Kilic-Okman T, Kucuk M, Altaner S 2003 Comparison of the effect of letrozole and clomiphene citrate on ovarian follicles, endometrium, and hormone levels in the rat. Fertility and Sterility 80, Kolibianakis EM, Albano, C, Camus M et al Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertility and Sterility 82, Metwally MF, Casper RF 2005 Single dose administration of an aromatase inhibitor for ovarian stimulation. Fertility and Sterility 83, Metwally MFM, Casper R 2004 Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. Journal of the Society for Gynecological Investigation 11, Metwally MFM, Casper RF 2003 Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Human Reproduction 18, Metwally MFM, Casper RF 2001 Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertility and Sterility 75, Metwally MF, Casper RF, Diamond MP 2005 The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment. Reproductive Biology and Endocrinology 3, 54. Papanikolaou EG, Bourgain C, Kolibianakis E et al Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Human Reproduction 20, Simon C, Cano F, Valbueña D et al Clinical evidence for a detrimental effect on uterine receptivity of high serum E2 concentrations in high and normal responder patients. Human Reproduction 10, Tavaniotou A, Albano C, Smitz J et al Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotrophins and gonadotropin-releasing hormone antagonist. Fertility and Sterility 77, Van Steirteghem A, Nagy P, Joris H et al Results of intracytoplasmic sperm injection with ejaculated, fresh and frozen thawed epididymal and testicular spermatozoa. Human Reproduction 13 (Suppl. 1), Weil S, Vendola K, Zhou J et al Androgen and folliclestimulating hormone interactions in primate ovarian follicle development. Journal of Clinical Endocrinology and Metabolism 84, Received 20 January 2006; refereed 9 February 2006; accepted 26 April
Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More informationArticle Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination
RBMOnline - Vol 13. No 2. 2006 208-212 Reproductive BioMedicine Online; www.rbmonline.com/article/2334 on web 30 May 2006 Article Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine
More informationEndometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study
Reproductive BioMedicine Online (2010) 21, 50 55 www.sciencedirect.com www.rbmonline.com ARTICLE Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot
More informationOriginal Article. Fauzia HaqNawaz 1*, Saadia Virk 2, Tasleem Qadir 3, Saadia Imam 3, Javed Rizvi 2
Original Article Comparison of Letrozole and Clomiphene Citrate Efficacy along with Gonadotrophins in Controlled Ovarian Hyperstimulation for Intrauterine Insemination Cycles Fauzia HaqNawaz 1*, Saadia
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationAbstract. Introduction. Materials and methods. Patients and methods
RBMOnline - Vol 8. No 3. 344-348 Reproductive BioMedicine Online; www.rbmonline.com/article/1178 on web 20 January 2004 Article Cumulative live birth rates after transfer of cryopreserved ICSI embryos
More informationShould we advise patients undergoing IVF to start a cycle leading to a day 3 or a day 5 transfer?
Human Reproduction Vol.19, No.11 pp. 2550 2554, 2004 Advance Access publication August 6, 2004 doi:10.1093/humrep/deh447 Should we advise patients undergoing IVF to start a cycle leading to a day 3 or
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationEHY Ng, WSB Yeung, PC Ho. Introduction
Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study EHY Ng, WSB Yeung, PC Ho
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
More informationAsimina Tavaniotou 1, Carola Albano 1, Johan Smitz 1 and Paul Devroey 1,2
Human Reproduction Vol.16, No.4 pp. 663 667, 2001 Comparison of LH concentrations in the early and midluteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist
More informationArticle Effect of cetrorelix dose on premature LH surge during ovarian stimulation
RBMOnline - Vol 16. No 6. 2008 772-777 Reproductive BioMedicine Online; www.rbmonline.com/article/3181 on web 18 April 2008 Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation
More informationProfound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF
Human Reproduction Vol.19, No.11 pp. 2490 2496, 2004 Advance Access publication August 19, 2004 doi:10.1093/humrep/deh471 Profound LH suppression after GnRH antagonist administration is associated with
More informationApproach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD
Approach to ovulation induction and superovulation in women with a history of infertility Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the
More informationModified natural cycle IVF and mild IVF: a 10 year Swedish experience
Reproductive BioMedicine Online (2010) 20, 156 162 www.sciencedirect.com www.rbmonline.com ARTICLE Modified natural cycle IVF and mild IVF: a 10 year Swedish experience Arthur Aanesen *, Karl-Gösta Nygren,
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationFactors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationSynchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
Reproductive BioMedicine Online (2012) 24, 527 531 www.sciencedirect.com www.rbmonline.com ARTICLE Synchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationCorifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial
Leader et al. Reproductive Biology and Endocrinology 2013, 11:52 RESEARCH Open Access Corifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationComparison of follitropin-b administered by a pen device with conventional syringe in an ART programme a retrospective study
Journal of Clinical Pharmacy and Therapeutics (2008) 33, 401 407 ORIGINAL ARTICLE Comparison of follitropin-b administered by a pen device with conventional syringe in an ART programme a retrospective
More informationAbstract. Introduction. RBMOnline - Vol 18. No Reproductive BioMedicine Online; on web 9 December 2008
RBMOnline - Vol 18. No 2. 2009 276-281 Reproductive BioMedicine Online; www.rbmonline.com/article/3602 on web 9 December 2008 Article GnRH antagonists and endometrial receptivity in oocyte recipients:
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationSpontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a randomized study
Reproductive BioMedicine Online (2011) 23, 484 489 www.sciencedirect.com www.rbmonline.com ARTICLE Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a
More informationArticle Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,
More informationSetting The setting was secondary care. The economic study was carried out in Turkey.
Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination Baysoy A, Serdaroglu H, Jamal H, Karatekeli E, Ozornek H, Attar E Record Status This is a critical abstract
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationCommon protocols in intra-uterine insemination cycles
Common protocols in intra-uterine insemination cycles Doç. Dr. Candan İltemir Duvan Turgut Özal Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum AD Ovulation induction with intra-uterine insemination
More informationA prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF
FVV IN OBGYN, 2012, 4 (2): 82-87 Original paper A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF S. GORDTS,
More informationLetrozole versus Clomiphene Citrate in Patients with Anovulatory Infertility
South Asian Letrozole Federation versus of Clomiphene Obstetrics Citrate and Gynecology, in Patients with January-April Anovulatory Infertility 2009;1(1):19-23 ORIGINAL STUDIES Letrozole versus Clomiphene
More informationComparison of the success rate of letrozole and clomiphene citrate. in women undergoing intrauterine insemination
Received: 10.2.2006 Accepted: 8.11.2006 Original Article Comparison of the success rate of letrozole and clomiphene citrate in women undergoing intrauterine insemination Robab Davar*, Maryam Asgharnia
More informationComparative Evaluation of Sequential Regimes of Gonadotropins with Clomiphene Citrate and Letrozole for Ovulation Induction
CODEN (USA)-IJPRUR, e-issn: 2348-6465 International Journal of Pharma Research and Health Sciences Available online at www.pharmahealthsciences.net Original Article Comparative Evaluation of Sequential
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationHum. Reprod. Advance Access published March 9, 2010
Human Reproduction, Vol.00, No.0 pp. 1 6, 2010 doi:10.1093/humrep/deq059 Hum. Reprod. Advance Access published March 9, 2010 ORIGINAL ARTICLE Infertility Avoidance of weekend oocyte retrievals during GnRH
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationInfertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations
Infertility Review and Update Clifford C. Hayslip MD Intrauterine Inseminations Beneficial effects of IUI not consistently documented in studies No deleterious effects on fertility 3-4 cycles of IUI should
More informationClinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve
Hindawi Publishing Corporation International Journal of Reproductive Medicine Volume 2014, Article ID 581451, 5 pages http://dx.doi.org/10.1155/2014/581451 Clinical Study Comparison of IVF Outcomes between
More informationInfertility. Thomas Lloyd and Samera Dean
Infertility Thomas Lloyd and Samera Dean Infertility Definition Causes Referral criteria Assisted reproductive techniques Complications Ethics What is infertility? Woman Reproductive age Has not conceived
More informationKey words: HCG versus GnRH agonist/ivf-gnrh antagonist cycles/ongoing pregnancy rates/oocyte maturation/rct
Human Reproduction Vol.20, No.10 pp. 2887 2892, 2005 Advance Access publication June 24, 2005. doi:10.1093/humrep/dei150 A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering
More informationA mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort
Chapter 6 A mild strategy in IVF results in favourable outcomes in terms of term live birth, cost and patient discomfort Heijnen E.M., Eijkemans M.J., De Klerk C., Polinder S., Beckers N.G., Klinkert E.R.,
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationA Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist
1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang
More informationORIGINAL ARTICLE Early pregnancy
Human Reproduction, Vol.26, No.5 pp. 1020 1024, 2011 Advanced Access publication on February 4, 2011 doi:10.1093/humrep/der012 ORIGINAL ARTICLE Early pregnancy Does cessation of progesterone supplementation
More informationReproductive Endocrinology & Infertility Glossary
Reproductive Endocrinology & Infertility Glossary The following is a glossary of terms you may hear during your association with the University of Mississippi Health Care's reproductive endocrinology and
More informationThe effect of luteal phase progesterone supplementation on natural frozen-thawed embryo transfer cycles
Original Article Obstet Gynecol Sci 2014;57(4):291-296 http://dx.doi.org/10.5468/ogs.2014.57.4.291 pissn 2287-8572 eissn 2287-8580 The effect of luteal phase progesterone supplementation on natural frozen-thawed
More informationArticle Prediction of pituitary down-regulation by evaluation of endometrial thickness in an IVF programme
RBMOnline - Vol 8. No 5. 2004 595-599 Reproductive BioMedicine Online; www.rbmonline.com/article/1065 on web 17 March 2004 Article Prediction of pituitary down-regulation by evaluation of endometrial thickness
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationProgesterone and clinical outcomes
Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationORIGINAL ARTICLE Reproductive endocrinology
Human Reproduction, Vol.24, No.11 pp. 2902 2909, 2009 Advanced Access publication on August 11, 2009 doi:10.1093/humrep/dep290 ORIGINAL ARTICLE Reproductive endocrinology Does the estradiol level on the
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationArticle Ovulation induction using low-dose step-up rfsh in Vietnamese women with polycystic ovary syndrome
RBMOnline - Vol 18. No 4. 2009 516-521 Reproductive BioMedicine Online; www.rbmonline.com/article/3636 on web 19 February 2009 Article Ovulation induction using low-dose step-up rfsh in Vietnamese women
More information2013 Sep.; 24(3):
Journal of Reproduction & Contraception doi: 10.7669/j.issn.1001-7844.2013.03.0159 2013 Sep.; 24(3):159-172 E-mail: randc_journal@163.com Comparison of the Effects and Safety of Mild Ovarian Stimulation
More information5/5/2010. Infertility FINANCIAL DISCLOSURE. Infertility Definition. Objectives. Normal Human Fertility. Normal Menstrual Cycle
Infertility FINANCIAL DISCLOSURE I HAVE NO FINANCIAL INTEREST IN ANY OF THE PRODUCTS MENTIONED IN MY PRESENTATION Bryan K. Rone, M.D. University of Kentucky Obstetrics and Gynecology I AM RECEIVING COMPENSATION
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationArticle Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study
RBMOnline - Vol 15. No 2. 2007 134-148 Reproductive BioMedicine Online; www.rbmonline.com/article/2711 on web 13 June 2007 Article Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationHongjuan Ye 1*, Hui Tian 1, Wen He 2, Qifeng Lyu 2, Yanping Kuang 2, Qiuju Chen 2* and Lihua Sun 1*
Ye et al. Reproductive Biology and Endocrinology (2018) 16:53 https://doi.org/10.1186/s12958-018-0373-7 RESEARCH Open Access Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes
More informationUse of clomiphene to prevent premature luteinizing hormone surge during controlled ovarian hyper stimulation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Bhandari S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Jun;5(6):1944-1948 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationArticle Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?
RBMOnline - Vol 16. No 5. 2008 664-670 Reproductive BioMedicine Online; www.rbmonline.com/article/3179 on web 11 March 2007 Article Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality
More informationAlternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment
Human Reproduction Vol., No.11 pp. 319 3197, 5 Advance Access publication July 1, 5. doi:.93/humrep/dei Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to
More information10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
More informationAromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Aromatase inhibition
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationThe Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (4), Page
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (4), Page 4382-4388 A Randomized Trial of Combined Letrozole with Metformin Versus Clomiphene Citrate with Metformin in Polycystic Ovary (PCOS)
More informationAbstract. Introduction. Materials and methods
RBMOnline - Vol 10. No 5. 2005 645 649 Reproductive BioMedicine Online; www.rbmonline.com/article/1518 on web 18 March 2005 Article Factors predicting IVF treatment outcome: a multivariate analysis of
More informationAbstract. Introduction
RBMOnline - Vol 19. No 6. 2009 888 898 Reproductive BioMedicine Online; www.rbmonline.com/article/ 3981 on web 30 September 2009 Review Role of androgens in the treatment of patients with low ovarian response
More informationModule 3. Infertility: Protocols and Patient Management
Module 3 Infertility: Protocols and Patient Management Ann Scalia, BSN, RN, CNOR Manager Clinical Education Specialists Mary Vietzke, BSN, RN Senior Clinical Educational Specialist Walgreens Faculty Ann
More informationFertility assessment and assisted conception
Fertility assessment and assisted conception Dr Geetha Venkat MD FRCOG Director Pulse Learning Women s health 14 September 2016 Disclosure statement Dr Venkat is a director of Harley Street Fertility Clinic.
More informationwww.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
More informationRelation between the Number and Size of Follicles in Ovulation Induction and the Rate of Pregnancy
Relation between the Number and Size of Follicles in Ovulation Induction and the Rate of Pregnancy Aseel Mosa Jabber M.SC.G.O. The department of Obstetrics and Gynecology, Faculty of Medicine Thi-qar university
More informationIntérêt de l hcg et induction de l ovulation. Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium
Intérêt de l hcg et induction de l ovulation Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium Conflict of interest The opinions expressed in this document are the opinions
More informationInfertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary
Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that
More informationINDICATIONS OF IVF/ICSI
PROCESS OF IVF/ICSI INDICATIONS OF IVF/ICSI IVF is most clearly indicated when infertility results from one or more causes having no other effective treatment; Tubal disease. In women with blocked fallopian
More informationInternational Federation of Fertility Societies. Global Standards of Infertility Care
International Federation of Fertility Societies Global Standards of Infertility Care Standard 8 Reducing the incidence of multiple pregnancy following treatment for infertility Name Version number Author
More informationFertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr.
Dr. Shahin Ghadir A Primary Care Approach to Diagnosing and Treating Infertility St. Charles Bend Grand Rounds November 30, 2018 I have no conflicts of interest to disclose. + About SCRC State-of-the-art
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More information% Oocyte Donation Pregnancyes (days 3)
Ovulation induction in oocyte donors Roma- September 2007 Dr. José Remohí Dr. Carmen Rubio Dr. Amparo Mercader Dr. Pilar Alama Dr. Marco Melo Evolution of oocyte donation cycles 1500 1500 1000 58% 661
More informationASSOCIATION OF 17 β ESTRADIOL LEVELS ON THE DAY OF hcg ADMINISTRATION WITH PREGNANCY RATE IN IVF (IN VITRO FERTILIZATION) PATIENTS
ASSOCIATION OF 17 β ESTRADIOL LEVELS ON THE DAY OF hcg ADMINISTRATION WITH PREGNANCY RATE IN IVF (IN VITRO FERTILIZATION) PATIENTS Ravikant Soni 1, * Bushra Fiza 1, Rati Mathur 2 and Maheep Sinha 1 1 Department
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Kasum M., Kurdija K., Orešković S., Čehić E., Pavičić-Baldani D., Škrgatić L. (2016) Combined ovulation triggering with GnRH agonist and hcg in IVF patients. Gynecological
More informationReproductive BioMedicine Online (2010) 20, 634 638 www.sciencedirect.com www.rbmonline.com ARTICLE In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationPituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.
UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.
More informationEffect of ovarian stimulation on oocyte quality and embryonic aneuploidy: a prospective, randomised controlled trial
FULL PROJECT TITLE: Effect of ovarian stimulation on oocyte quality and embryonic aneuploidy: a prospective, randomised controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM)
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationNo association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH
Reproductive BioMedicine Online (2011) 23, 457 465 www.sciencedirect.com www.rbmonline.com ARTICLE No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant
More informationKisspeptin: A Potential Factor for Unexplained Infertility and Impaired Embryo Implantation
Original Article Kisspeptin: A Potential Factor for Unexplained Infertility and Impaired Embryo Implantation Aaida Mumtaz, MBBS. 1#, Aqsa Khalid, MBBS. 1#, Zehra Jamil, M.Phil. 2, Syeda Sadia Fatima, Ph.D.
More informationThe psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy
Human Reproduction Vol.22, No.9 pp. 2554 2558, 2007 Advance Access publication on June 23, 2007 doi:10.1093/humrep/dem171 The psychological impact of IVF failure after two or more cycles of IVF with a
More informationIVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman
IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major
More information